HypoCol (red yeast rice) lowers plasma cholesterol - a randomized placebo controlled study

被引：57

作者：

Bogsrud, Martin Proven ^{[1
]}

Ose, Leiv ^{[1
]}

Langslet, Gisle ^{[1
]}

Ottestad, Inger ^{[3
]}

Strom, Ellen Charlotte ^{[1
]}

Hagve, Tor-Arne ^{[2
,4
]}

Retterstol, Kjetil ^{[1
,5
]}

机构：

[1] Oslo Univ Hosp, Lipid Clin, Rikshosp, Oslo, Norway

[2] Oslo Univ Hosp, Dept Med Biochem, Rikshosp, Oslo, Norway

[3] Akershus Univ Coll, Lillestrom, Norway

[4] Akershus Univ Hosp, Fac Div, Lorenskog, Norway

[5] Norwegian Med Agcy, Oslo, Norway

来源：

SCANDINAVIAN CARDIOVASCULAR JOURNAL | 2010年 / 44卷 / 04期

关键词：

CORONARY-HEART-DISEASE; XUEZHIKANG; EXTRACT;

D O I：

10.3109/14017431003624123

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. The primary endpoint in our study was to investigate the effect of a red yeast rice (RYR) product on plasma lipids. Design. A randomized, double-blind, placebo controlled study was performed. Patients were randomized to either RYR (HypoCol, 4 capsules/day) (n=22) or placebo (n=20) for 16 weeks. Inclusion criteria were male or female, 18-75 years, LDL-cholesterol between 3.0 and 6.0 mmol/L, fasting triglyceride level less than 4.5 mmol/L. Results. Patients receiving RYR experienced a significant reduction in LDL-cholesterol (23.0%) and total cholesterol (15.5%) compared to placebo after 16 weeks of treatment (p<0.001). Conclusion. The tested red yeast rice product demonstrated a significant cholesterol lowering effect compared to placebo, and was well tolerated in this Caucasian population.

引用

页码：197 / 200

页数：4

共 15 条

[1] Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients A Randomized Trial [J].

Becker, David J. ;

Gordon, Ram Y. ;

Halbert, Steven C. ;

French, Benjamin ;

Morris, Patti B. ;

Rader, Daniel J. .

ANNALS OF INTERNAL MEDICINE, 2009, 150 (12) :830-U30

[2] The origin of the statins (Reprinted from Atherosclerosis XIII: Proceedings of the XIII International Symposium on Atherosclerosis., pg 3-8, 2004) [J].

Endo, A .

ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (03) :125-130

[3]

Heber D, 1999, AM J CLIN NUTR, V69, P231

[4] An analysis of nine proprietary Chinese red yeast rice dietary supplements: Implications of variability in chemical profile and contents [J].

Heber, D ;

Lembertas, A ;

Lu, QY ;

Bowerman, S ;

Go, VLW .

JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2001, 7 (02) :133-139

[5]

LI C, 1995, INF CHIN PHARM SOC, V12, P12

[6] Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry [J].

Li, YG ;

Zhang, F ;

Wang, ZT ;

Hu, ZB .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 35 (05) :1101-1112

[7] Plasma clearance of lovastatin versus Chinese red yeast rice in healthy volunteers [J].

Li, ZP ;

Seeram, NP ;

Lee, R ;

Thames, G ;

Minutti, C ;

Wang, HJ ;

Heber, D .

JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2005, 11 (06) :1031-1038

[8] Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: A meta-analysis of randomized controlled trials [J].

Liu J. ;

Zhang J. ;

Shi Y. ;

Grimsgaard S. ;

Alraek T. ;

Fønnebø V. .

Chinese Medicine, 1 (1)

[9] Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease [J].

Liu, L ;

Zhao, SP ;

Cheng, YC ;

Li, YL .

CLINICAL CHEMISTRY, 2003, 49 (08) :1347-1352

[10] Effect of Xuezhikang, an extract from red yeast chinese rice, on coronary events in a Chinese population with previous myocardial infarction [J].

Lu, Zongliang ;

Kou, Wenrong ;

Du, Baomin ;

Wu, Yangfeng ;

Zhao, Shuiping ;

Brusco, Osvaldo A. ;

Morgan, John M. ;

Capuzzi, David M. .

AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (12) :1689-1693

← 1 2 →